This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ziarco Pharma Ltd
Drug Names(s): PF-3893787, ZPL-3893787, ZPL389
Description: ZPL-3893787 is a proprietary compound targeting the Histamine H4 Receptor (H4R). In targeting H4R, ZPL-3893787 has the potential to target the various functional inflammatory responses that is mediated by histamine (i.e. chemotaxis, mobilization of intracellular calcium). ZPL-3893787 and H4R antagonists in general have indicated utility in treating a variety of disease indications, including allergic and inflammatory conditions affecting the lung, skin and gastrointestinal system, inflammatory and neuropathic pain, acute and chronic pruritus, and hearing disorders. The recent identification of H4R in the nervous system and certain regions of the brain may also suggest a role in central functions.
Ziarco and Pfizer
In November 2012, Ziarco entered into an agreement with Pfizer for the exclusive worldwide rights to commercialize a portfolio of clinical, preclinical and research assets. In return, Pfizer will receive equity as well as certain product-based milestone and royalty payments.
Partners: Pfizer Inc.
Additional information available to subscribers only: